<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Exp Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Exp. Nephrol</journal-id><journal-title-group><journal-title>Clinical and Experimental Nephrology</journal-title></journal-title-group><issn pub-type="ppub">1342-1751</issn><issn pub-type="epub">1437-7799</issn><publisher><publisher-name>Springer Japan</publisher-name><publisher-loc>Tokyo</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27783276</article-id><article-id pub-id-type="pmc">5698362</article-id><article-id pub-id-type="publisher-id">1340</article-id><article-id pub-id-type="doi">10.1007/s10157-016-1340-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1279-6400</contrib-id><name><surname>Saito</surname><given-names>Takao</given-names></name><address><phone>81-92-713-0468</phone><email>tsaito@fukuoka-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Iwano</surname><given-names>Masayuki</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Matsumoto</surname><given-names>Koichi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mitarai</surname><given-names>Tetsuya</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Yokoyama</surname><given-names>Hitoshi</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Yorioka</surname><given-names>Noriaki</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Nishi</surname><given-names>Shinichi</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Yoshimura</surname><given-names>Ashio</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Sato</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Ogahara</surname><given-names>Satoru</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Sasatomi</surname><given-names>Yoshie</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Kataoka</surname><given-names>Yasufumi</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Ueda</surname><given-names>Shiro</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Koyama</surname><given-names>Akio</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Maruyama</surname><given-names>Shoichi</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Nangaku</surname><given-names>Masaomi</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Imai</surname><given-names>Enyu</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Matsuo</surname><given-names>Seiichi</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Tomino</surname><given-names>Yasuhiko</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><collab>The Refractory Nephrotic Syndrome Study Group</collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0672 2176</institution-id><institution-id institution-id-type="GRID">grid.411497.e</institution-id><institution>Professor Emeritus, </institution><institution>Fukuoka University, and Sanko Clinic, </institution></institution-wrap>4-9-3 Ropponmatsu, Chuo-ku, Fukuoka, 810-0044 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0692 8246</institution-id><institution-id institution-id-type="GRID">grid.163577.1</institution-id><institution>Division of Nephrology, </institution><institution>Department of General Medicine, Faculty of Medical Sciences, University of Fukui, </institution></institution-wrap>Fukui, Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2149 8846</institution-id><institution-id institution-id-type="GRID">grid.260969.2</institution-id><institution>The University Research Center, </institution><institution>General Science Institute, School of Medicine, Nihon University, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff4"><label>4</label>Department of Nephrology and Blood Purification, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0265 5359</institution-id><institution-id institution-id-type="GRID">grid.411998.c</institution-id><institution>Division of Nephrology, </institution><institution>Kanazawa Medical University School of Medicine, </institution></institution-wrap>Ishikawa, Japan </aff><aff id="Aff6"><label>6</label>Hiroshima Kidney Organization, Hiroshima, Japan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1092 3077</institution-id><institution-id institution-id-type="GRID">grid.31432.37</institution-id><institution>Division of Nephrology and Kidney Center, </institution><institution>Kobe University Graduate School of Medicine, </institution></institution-wrap>Kobe, Japan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1764 9041</institution-id><institution-id institution-id-type="GRID">grid.412808.7</institution-id><institution>Division of Nephrology, </institution><institution>Department of Internal Medicine, Showa University Fujigaoka Hospital, </institution></institution-wrap>Yokohama, Japan </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2248 6943</institution-id><institution-id institution-id-type="GRID">grid.69566.3a</institution-id><institution>Division of Nephrology, </institution><institution>Tohoku University Graduate School of Medicine, </institution></institution-wrap>Sendai, Japan </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0672 2176</institution-id><institution-id institution-id-type="GRID">grid.411497.e</institution-id><institution>Division of Nephrology and Rheumatology, </institution><institution>Faculty of Medicine, Fukuoka University, </institution></institution-wrap>Fukuoka, Japan </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0672 2176</institution-id><institution-id institution-id-type="GRID">grid.411497.e</institution-id><institution>Department of Pharmaceutical Care and Health Sciences, </institution><institution>Faculty of Pharmaceutical Sciences, Fukuoka University, </institution></institution-wrap>Fukuoka, Japan </aff><aff id="Aff12"><label>12</label>Ueda Clinic, Chiba, Japan </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2369 4728</institution-id><institution-id institution-id-type="GRID">grid.20515.33</institution-id><institution>Professor Emeritus, </institution><institution>Tsukuba University, </institution></institution-wrap>Ibaraki, Japan </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0943 978X</institution-id><institution-id institution-id-type="GRID">grid.27476.30</institution-id><institution>Department of Nephrology, </institution><institution>Nagoya University Graduate School of Medicine, </institution></institution-wrap>Nagoya, Japan </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2151 536X</institution-id><institution-id institution-id-type="GRID">grid.26999.3d</institution-id><institution>Division of Nephrology and Endocrinology, </institution><institution>University of Tokyo School of Medicine, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff16"><label>16</label>Nakayamadera Imai Clinic, Hyogo, Japan </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1762 2738</institution-id><institution-id institution-id-type="GRID">grid.258269.2</institution-id><institution>Professor Emeritus, </institution><institution>Juntendo University, </institution></institution-wrap>Tokyo, Japan </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>21</volume><issue>6</issue><fpage>961</fpage><lpage>970</lpage><history><date date-type="received"><day>25</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>4</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">We designed a prospective and randomized trial of mizoribine (MZR) therapy combined with prednisolone (PSL) for idiopathic membranous nephropathy (IMN) with steroid-resistant nephrotic syndrome (SRNS).</p></sec><sec><title>Methods</title><p id="Par2">Patients with IMN were divided into 2 groups, and MZR combined with PSL was administered for 2&#x000a0;years. PSL was initially prescribed at 40&#x000a0;mg/day and tapered. MZR was given once-a-day at 150&#x000a0;mg and 3-times-a-day at 50&#x000a0;mg each to groups 1 and 2. Serum MZR concentrations from 0 to 4&#x000a0;h after administration were examined within one month of treatment. The concentration curve and peak serum level (<italic>C</italic>
<sub>max</sub>) of MZR were estimated by the population pharmacokinetic (PPK) parameters of MZR.</p></sec><sec><title>Results</title><p id="Par3">At 2&#x000a0;years, 10 of 19 patients (52.6&#x000a0;%) in group 1 and 7 of 18 patients (38.9&#x000a0;%) in group 2 achieved complete remission (CR). The time-to-remission curve using the Kaplan&#x02013;Meier technique revealed an increase in the cumulative CR rate in group 1, but no significant difference between the groups. Meanwhile, there was a significant difference in <italic>C</italic>
<sub>max</sub> between groups 1 and 2 (mean&#x000a0;&#x000b1;&#x000a0;SD: 1.20&#x000a0;&#x000b1;&#x000a0;0.52 vs. 0.76&#x000a0;&#x000b1;&#x000a0;0.39&#x000a0;&#x003bc;g/mL, <italic>p</italic>&#x000a0;=&#x000a0;0.04), and <italic>C</italic>
<sub>max</sub> levels in CR cases were significantly higher than those in non-CR cases. Receiver operating characteristic analysis showed that <italic>C</italic>
<sub>max</sub> more than 1.1&#x000a0;&#x000b5;g/mL was necessary for CR in once-a-day administration.</p></sec><sec><title>Conclusion</title><p id="Par4">Administration of MZR once a day is useful when combined with PSL for treatment of IMN with SRNS. In addition, it is important to assay the serum concentration of MZR and to determine <italic>C</italic>
<sub>max</sub>, and more than 1.1&#x000a0;&#x000b5;g/mL of <italic>C</italic>
<sub>max</sub> is necessary for CR.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Mizoribine</kwd><kwd>Idiopathic membranous nephropathy</kwd><kwd>Steroid-resistant nephrotic syndrome</kwd><kwd>Once-a-day administration</kwd><kwd>Estimated serum concentration curve</kwd></kwd-group><funding-group><award-group><funding-source><institution>Progressive Renal Research Projects of the Ministry of Health, Labor and Welfare, Japan </institution></funding-source></award-group><award-group><funding-source><institution>the Japan Kidney Foundation</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Japanese Society of Nephrology 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Idiopathic membranous nephropathy (IMN) is the most representative disease associated with steroid-resistant nephrotic syndrome (SRNS) in adults. In our cohort study of 1000 cases in Japan, the overall renal survival rate for patients with IMN, in which end-stage renal disease (ESRD) was the end point, was 95.8, 90.3, 81.1 and 60.5&#x000a0;% at 5, 10, 15 and 20&#x000a0;years after onset, respectively, and the prognosis was significantly improved by reduction of proteinuria [<xref ref-type="bibr" rid="CR1">1</xref>]. Accordingly, the primary aims of treatment are to induce a lasting reduction in proteinuria. Although a combination of steroids and immunosuppressants, e.g., alkylating agents [<xref ref-type="bibr" rid="CR2">2</xref>] and calcineurin inhibitors [<xref ref-type="bibr" rid="CR3">3</xref>], has been recommended by some guidelines for this purpose, the harmful side effects preclude long-term use of these medicines. On the other hand, several studies have shown that a combination of steroids and mizoribine (MZR), one of the purine metabolism inhibitors, is effective in patients with nephrotic syndrome [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>] as well as transplant recipients without any serious adverse reactions [<xref ref-type="bibr" rid="CR8">8</xref>]. MZR is an imidazole nucleotide that exerts selective inhibitory effects on inosine-5-monophosphate dehydrogenase, an enzyme in the de-novo purine nucleoside synthesis system [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], which are very similar to those of mycophenolate mofetil (MMF) and result in suppression of T and B lymphocyte proliferation. Moreover, a recent study has suggested that MZR directly prevents podocyte injury and preserves nephrin structure, leading to a reduction of urinary protein [<xref ref-type="bibr" rid="CR11">11</xref>]. In fact, this mechanism may clinically reduce the incidence of severe adverse drug reactions. Accordingly, in Japan, MZR is approved as an insurance application medicine for SRNS, and administration at 50&#x000a0;mg 3-times-a-day combined with steroids is recommended. However, it has been pointed out that 3-times-a-day administration cannot provide a serum concentration of MZR sufficiently effective for remission, and that once-a-day administration is more advantageous [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par6">To investigate this issue, we designed a prospective, open-label, randomized trial to compare the effect of once-a-day administration of MZR with that of conventional 3-times-a-day administration for IMN with associated SRNS. In addition, the serum concentration curve and the peak serum level (<italic>C</italic>
<sub>max</sub>) of MZR after administration, which may reflect the efficacy of MZR, were estimated using serum MZR concentrations assayed at several time points. These estimations were based on a population pharmacokinetic (PPK) analysis of MZR in patients with kidney diseases at Fukuoka University Hospital using a nonlinear mixed effects model (NONMEM) program.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par7">This study was entered in the University Hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR) under trial identification No. UMIN C000000368.</p><sec id="Sec3"><title>Patients</title><p id="Par8">SRNS patients (age 16&#x02013;75&#x000a0;years) with IMN diagnosed by renal biopsy were enrolled through computerized registration from kidney centers in Japan between 2004 and 2007. Membranous nephropathy secondary to systemic diseases, e.g., diabetic nephropathy and collagen diseases, were excluded at registration. Nephrotic syndrome (NS) was defined according to the standard criteria used in Japan [<xref ref-type="bibr" rid="CR1">1</xref>]: (1) urine protein (UP) excretion &#x0003e;3.5&#x000a0;g/day, (2) serum albumin &#x0003c;3.0&#x000a0;g/dL or serum total protein &#x0003c;6.0&#x000a0;g/dL, (3) presence of edema, and (4) total cholesterol &#x0003e;250&#x000a0;mg/dL. At least the first and second criteria were necessary for the diagnosis. SRNS was determined when patients did not achieve complete remission (CR) or incomplete remission (ICR) 1 (as described in the &#x0201c;Clinical assessment&#x0201d; section) after 4&#x000a0;weeks of prednisolone (PSL) therapy at 40&#x02013;60&#x000a0;mg/day. The inclusion and exclusion criteria are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Inclusion and exclusion criteria</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Inclusion criteria</td></tr><tr><td align="left"> &#x000a0;Age between 16 and 75&#x000a0;years</td></tr><tr><td align="left"> &#x000a0;UP &#x02267;3.5&#x000a0;g/day and serum albumin level &#x02266;3.0&#x000a0;g/dL</td></tr><tr><td align="left"> &#x000a0;PSL treatment alone for &#x0003e;4&#x000a0;weeks did not decrease UP to &#x0003c;1&#x000a0;g/day</td></tr><tr><td align="left"> &#x000a0;Membranous nephropathy was diagnosed by renal biopsy</td></tr><tr><td align="left"> &#x000a0;No history of treatment with MZR before registration</td></tr><tr><td align="left"> &#x000a0;Informed consent form signed voluntarily by the participant</td></tr><tr><td align="left">Exclusion criteria</td></tr><tr><td align="left"> &#x000a0;Patients with creatinine clearance &#x0003c;50&#x000a0;mL/min or serum creatinine &#x0003e;2&#x000a0;mg/dL</td></tr><tr><td align="left"> &#x000a0;Patients with a history of severe hypersensitive reaction to MZR</td></tr><tr><td align="left"> &#x000a0;Patients previously treated with MZR</td></tr><tr><td align="left"> &#x000a0;Patients with a white blood cell count of &#x0003c;3000/mm<sup>3</sup> in peripheral blood</td></tr><tr><td align="left"> &#x000a0;Patients currently pregnant, suspected to be pregnant, or nursing</td></tr><tr><td align="left"> &#x000a0;Patients with any severe complication</td></tr><tr><td align="left"> &#x000a0;Patients with any severe bacterial, fungal, or viral infection</td></tr><tr><td align="left"> &#x000a0;Patients determined to be inappropriate for participation in the study by an investigator</td></tr></tbody></table><table-wrap-foot><p>
<italic>UP</italic> urine protein, <italic>PSL</italic> prednisolone, <italic>MZR</italic> mizoribine</p></table-wrap-foot></table-wrap>
</p><p id="Par9">Renal histology was assessed according to the following 5 parameters: presence of global sclerosis and segmental sclerosis in glomeruli, severity of tubulointerstitial changes, occurrence of vascular lesions, and ultrastructural stage of glomerular lesions according to the criteria of Ehrenreich and Churg [<xref ref-type="bibr" rid="CR14">14</xref>]. These changes were estimated semiquantitatively, as we have previously reported [<xref ref-type="bibr" rid="CR1">1</xref>], and compared between the groups.</p></sec><sec id="Sec4"><title>Trial design</title><p id="Par10">Patients were divided prospectively and randomly into 2 groups (groups 1 and 2). Combined administration of PSL and MZR was continued for 24&#x000a0;months. PSL was initially prescribed at 40&#x000a0;mg/day and tapered gradually to &#x0003c;10&#x000a0;mg/day by 48&#x000a0;weeks. In group 1, MZR was given orally once-a-day after breakfast at 150&#x000a0;mg. In group 2, MZR was given 3-times-a-day after meals at 50&#x000a0;mg each. Other agents, including antihypertensive, antidyslipidemic, antiplatelet and anticoagulant drugs, were allowed unless their combination with MZR was contraindicated. Biochemical data, including total protein, albumin, urea nitrogen, creatinine, uric acid, total cholesterol, aspartate aminotransaminase (AST) and alanine aminotransferase (ALT) in serum, and 24-h UP, were assayed at 0, 3, 6, 12 and 24&#x000a0;months.</p></sec><sec id="Sec5"><title>Clinical assessment</title><p id="Par11">Clinical assessment of treatment outcomes was done on the basis of changes in proteinuria and renal function, partly modified from the previous criteria used in Japan [<xref ref-type="bibr" rid="CR1">1</xref>]. Briefly, CR was defined as UP &#x0003c;0.3&#x000a0;g/day. ICR was defined as the resolution of NS but with continuing overt proteinuria, and was divided into 2 grades: ICR1 and ICR2 for UP values of 0.3&#x02013;0.99 and 1.0&#x02013;3.5&#x000a0;g/day, respectively. No response (NR) was defined as the persistence of NS. Since, in a previous study, patients with ICR1 had shown a favorable prognosis almost equal to CR [<xref ref-type="bibr" rid="CR1">1</xref>], we considered CR&#x000a0;+&#x000a0;ICR1 as remission. For renal function, 3 categories were defined on the basis of serum creatinine concentration: (1) normal renal function &#x0003c;1.5&#x000a0;mg/dL, (2) renal insufficiency 1.5&#x02013;3.0&#x000a0;mg/dL, and (3) end-stage renal disease &#x0003e;3.0&#x000a0;mg/dL.</p></sec><sec id="Sec6"><title>MZR concentration assay</title><p id="Par12">For monitoring of MZR levels in 22 patients (12 in group 1 and 10 in group 2), serum MZR concentrations were assayed from 0 to 4&#x000a0;h of administration (<italic>C</italic>
<sub>0&#x02013;4</sub>) within the first month of treatment using high-performance liquid chromatography (HPLC) according to the method of Hosotsubo et al. [<xref ref-type="bibr" rid="CR15">15</xref>]. The MZR quantification limit was 0.05&#x000a0;&#x003bc;g/mL in serum.</p></sec><sec id="Sec7"><title>PPK analysis in patients with kidney disease</title><p id="Par13">Using serum MZR concentration data for a total of 304 time points in 64 adult patients with various kidney diseases assayed previously at Fukuoka University Hospital, PPK parameters and their inter-individual variations were estimated by NONMEM program according to the estimation method employed previously in studies of healthy male volunteers [<xref ref-type="bibr" rid="CR16">16</xref>] and adult renal transplant recipients [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par14">The one-compartment model with first-order absorption was parameterized in terms of absorption lag time (ALAG), absorption rate constant (KA), the apparent volume of distribution (V/F), and oral clearance (CL/F). The predicted population mean V/F and CL/F of MZR were modeled using the following equations:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$CL/F\text{ = }\theta_{1} \times {\text{CLcr }}\left( {\text{L/h}} \right)$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>F</mml:mi><mml:mspace width="0.333333em"/><mml:mtext>=</mml:mtext><mml:mspace width="0.333333em"/><mml:msub><mml:mi mathvariant="italic">&#x003b8;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mtext>CLcr</mml:mtext><mml:mspace width="0.333333em"/></mml:mrow><mml:mfenced close=")" open="("><mml:mtext>L/h</mml:mtext></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="10157_2016_1340_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>
<disp-formula id="Equb"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V/F = \theta_{ 2} \times {\text{WT}}\text{ }(L)$$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mrow><mml:mi>V</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="italic">&#x003b8;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&#x000d7;</mml:mo><mml:mtext>WT</mml:mtext><mml:mspace width="0.333333em"/><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>L</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xlink:href="10157_2016_1340_Article_Equb.gif" position="anchor"/></alternatives></disp-formula>
</p></sec><sec id="Sec8"><title>Estimated serum MZR concentration in IMN patients</title><p id="Par15">The serum MZR concentration curves and maximum concentrations (<italic>C</italic>
<sub>max</sub>) for 22 patients in groups 1 and 2 were estimated simultaneously using assayed <italic>C</italic>
<sub>0&#x02013;4</sub> by Bayesian inference based on the above PPK parameters. The detailed methods were described in previous papers [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The data were compared between each administration group of IMN patients.</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par16">Values are given as mean&#x000a0;&#x000b1;&#x000a0;SD or median (interquartile range). Differences in clinical characteristics between the 2 groups were evaluated using Student&#x02019;s <italic>t</italic> and Mann&#x02013;Whitney <italic>U</italic> tests for continuous variables and Fisher&#x02019;s exact test for categorical variables. The incidence of remission (CR&#x000a0;+&#x000a0;ICR1) or CR was compared using Fisher&#x02019;s exact test. Time-to-remission or CR curves for the 2 therapy groups were estimated using the Kaplan&#x02013;Meier technique, and the curves were compared using the log-rank test. Receiver operating characteristic (ROC) curve analysis was used to test the prognostic value of the serum MZR concentration expressed as <italic>C</italic>
<sub>max</sub> and to determine the optimum cutoff point for prediction of CR.</p><p id="Par17">All statistical analyses were performed using SPSS for Windows version 22.0 (SPSS Japan Inc., Tokyo, Japan).</p></sec></sec><sec id="Sec10"><title>Results</title><p id="Par18">A flowchart of the study design, including patient enrollment and treatment assignment, is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Flowchart of the study design: enrollment of patients and treatment assignment</p></caption><graphic xlink:href="10157_2016_1340_Fig1_HTML" id="MO3"/></fig>
</p><sec id="Sec11"><title>Patients</title><p id="Par19">Fifty-one patients at 23 kidney centers in Japan were registered according to the inclusion criteria, between April 2004 and December 2007, and 26 and 25 patients were randomly enrolled in the once-a-day (group 1) and 3-times-a-day (group 2) administration groups, respectively. However, 6 patients in each group declined to participate in this study before MZR treatment. Moreover, one patient in each group showed urine protein under 1&#x000a0;g/day just before MZR treatment was withdrawn from this study. Consequently, 19 and 18 patients were treated with PSL and MZR in groups 1 and 2, respectively. The baseline clinical characteristics of all patients are summarized in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The data were at 4&#x000a0;weeks of PSL-alone treatment and just before PSL and MZR combined therapy. There were no significant inter-group differences in any of the characteristics. Furthermore, none of 5 renal histology parameters estimated semiquantitatively showed any significant differences between the groups (data not shown).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Baseline characteristics of patients with idiopathic membranous nephropathy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">Group 1 (<italic>n</italic>&#x000a0;=&#x000a0;19)</th><th align="left">Group 2 (<italic>n</italic>&#x000a0;=&#x000a0;18)</th><th align="left">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left">Gender (male/female)</td><td align="left">15:4</td><td align="left">14:4</td><td align="left">0.93</td></tr><tr><td align="left">Age (years)</td><td align="left">60 (35&#x02013;70)</td><td align="left">60 (43&#x02013;74)</td><td align="left">0.75</td></tr><tr><td align="left">Urine protein (g/day)</td><td align="left">3.7 (1.0&#x02013;7.5)</td><td align="left">3.3 (1.3&#x02013;7.1)</td><td align="left">0.80</td></tr><tr><td align="left" colspan="4">Serum levels</td></tr><tr><td align="left">&#x000a0;Urea nitrogen (mg/dL)</td><td align="left">14.5 (7.0&#x02013;23.7)</td><td align="left">15.1 (7.0&#x02013;29.0)</td><td align="left">0.81</td></tr><tr><td align="left">&#x000a0;Creatinine (mg/dL)</td><td align="left">0.8 (0.5&#x02013;1.3)</td><td align="left">0.9 (0.6&#x02013;1.4)</td><td align="left">0.37</td></tr><tr><td align="left">&#x000a0;Uric acid (mg/dL)</td><td align="left">5.7 (3.7&#x02013;8.5)</td><td align="left">6.4 (4.4&#x02013;9.2)</td><td align="left">0.27</td></tr><tr><td align="left">&#x000a0;Total protein (g/dL)</td><td align="left">4.7 (3.9&#x02013;5.5)</td><td align="left">4.7 (3.3&#x02013;6.2)</td><td align="left">0.15</td></tr><tr><td align="left">&#x000a0;Albumin (g/dL)</td><td align="left">2.5 (1.8&#x02013;3.4)</td><td align="left">2.6 (1.0&#x02013;3.9)</td><td align="left">0.59</td></tr><tr><td align="left">&#x000a0;Total cholesterol (mg/dL)</td><td align="left">351 (188&#x02013;769)</td><td align="left">300 (187&#x02013;390)</td><td align="left">0.17</td></tr></tbody></table><table-wrap-foot><p>The data were at 4&#x000a0;weeks of PSL-alone treatment and just before PSL and MZR combined therapy</p><p>Age and laboratory data are shown as medians (interquartile range)</p><p>The <italic>p</italic> values were evaluated by Fisher&#x02019;s exact test for gender and Mann&#x02013;Whitney <italic>U</italic> test for the others</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>Responses in the once-a-day (group 1) and 3-times-a-day (group 2) MZR administration groups</title><p id="Par20">The responses at one and 2&#x000a0;years of treatment are shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. Within 1&#x000a0;year of treatment, 9 of 19 patients reached CR in group 1. But one relapsed into ICR2 by 12&#x000a0;months and another was withdrawn by thyroid tumor at 6&#x000a0;months. Accordingly, 7 of 19 patients (36.8&#x000a0;%) in group 1 and 9 of 18 patients (50.0&#x000a0;%) in group 2 achieved CR without relapse at one year. When ICR-1 was added to remission with CR, 10 of 19 patients (52.6&#x000a0;%) in group 1 and 13 of 18 patients (72.2&#x000a0;%) in group 2 achieved remission. Five patients in group 1 were withdrawn because of non-compliance (3 patients), brain tumor (one patient) and thyroid tumor (one patient). In the intention-to-treat analysis, these results did not reveal any significant difference between the groups.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Remission and withdrawal rates of groups 1 and 2 at 12 and 24&#x000a0;months. Patients were divided according to MZR administration frequency&#x02014;once-a-day (group 1) and 3-times-a-day (group 2)</p></caption><graphic xlink:href="10157_2016_1340_Fig2_HTML" id="MO4"/></fig>
</p><p id="Par21">By 2&#x000a0;years, 3 more patients in group 1 reached CR from ICR, and finally 10 patients achieved CR and no patients relapsed, although two ICR2 patients were deteriorated to nephrotic range and withdrawn by removal, respectively. In group 2, one patient reached CR from ICR1, but 3 CR patients relapsed to ICR1 (one patient) and ICR2 (2 patients). On the other hand, two ICR2 patients at 1&#x000a0;year was improved to ICR1 and withdrawn by prescription change, respectively.</p><p id="Par22">As shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, 13 of 19 patients and 17 of 18 patients completely received MZR treatment combined with PSL for 2&#x000a0;years. With 2&#x000a0;years of treatment, 10 of 19 patients (52.6&#x000a0;%) in group 1 and 7 of 18 patients (38.9&#x000a0;%) in group 2 achieved CR without relapse, and 12 of 19 patients (63.2&#x000a0;%) in group 1 and 12 of 18 patients (66.7&#x000a0;%) in group 2 achieved remission. Accordingly, in the intention-to-treat analysis, these results did not yield a significant difference between the groups.</p><p id="Par23">Kaplan&#x02013;Meier analysis of the time-to-remission curves revealed an increase in the cumulative CR rate in group 1 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>), but log-rank test demonstrated no significant inter-group difference.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Probability of cumulative complete remission (CR) for patients treated with PSL and MZR by Kaplan&#x02013;Meier analysis. Cumulative number of CR includes relapse cases. Group 1 showed a slightly higher rate of CR but there was no significant difference between groups 1 and 2</p></caption><graphic xlink:href="10157_2016_1340_Fig3_HTML" id="MO5"/></fig>
</p></sec><sec id="Sec13"><title>Other clinical and laboratory findings</title><p id="Par24">No patients in either group showed serum urea nitrogen or creatinine levels reflecting abnormal renal function. Low total protein and albumin and high total cholesterol concentrations in serum were normalized as remission of NS was achieved. There were no significant differences in these parameters between groups 1 and 2 during treatment. Serum uric acid levels, which are sometimes reported to be elevated in patients receiving MZR, were slightly increased in group 1 during treatment but were not significantly higher than those in group 2 (mean&#x000a0;&#x000b1;&#x000a0;SD 7.52&#x000a0;&#x000b1;&#x000a0;1.31 vs. 6.68&#x000a0;&#x000b1;&#x000a0;1.45&#x000a0;mg/dL at 2&#x000a0;years of MZR treatment, not significant). Gout was not recognized in any of the patients. AST and ALT levels increased temporarily in some patients in both groups, but were finally normalized, and no patients had serious liver disease.</p><p id="Par25">As described above, two patients in group 1 had to be withdrawn due to development of brain and thyroid tumors, respectively. However, these were accidental complications, and no adverse event related to the use of MZR occurred.</p></sec><sec id="Sec14"><title>PPK parameters of MZR</title><p id="Par26">Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows the data of 64 adult patients with kidney disease for PPK analysis. PPK parameters and their inter-individual variations were estimated by NONMEM analysis and compared with those in previous studies [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>] (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). The mean values of ALAG, KA, V/F, and CL/F were 0.675&#x000a0;h, 0.723&#x000a0;h<sup>&#x02212;1</sup>, 0.744&#x000a0;&#x000d7;&#x000a0;WT L, and 2.1&#x000a0;&#x000d7;&#x000a0;CLcr&#x000a0;&#x000d7;&#x000a0;60/1000 L/h, respectively. The values of PPK parameters in adult patients with kidney disease were almost the same as those in healthy male volunteers [<xref ref-type="bibr" rid="CR16">16</xref>] and adult renal transplant recipients [<xref ref-type="bibr" rid="CR17">17</xref>].<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>The data of adult patients with kidney disease for PPK analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="11">(a) Demographic data of patients used in PPK analysis (<italic>n</italic>&#x000a0;=&#x000a0;64)</th></tr><tr><th align="left">Gender (male/female)<break/>31:33</th><th align="left">Mean</th><th align="left">SD</th><th align="left">Mini</th><th align="left">Median</th><th align="left">Max</th><th align="left"/><th align="left"/><th align="left"/><th align="left"/><th align="left"/></tr></thead><tbody><tr><td align="left">&#x000a0;Age (years)</td><td char="." align="char">53.8</td><td char="." align="char">14.9</td><td char="." align="char">19.0</td><td char="." align="char">54.5</td><td char="." align="char">80.0</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Body weight: WT (kg)</td><td char="." align="char">57.0</td><td char="." align="char">12.4</td><td char="." align="char">27.8</td><td char="." align="char">56.7</td><td char="." align="char">93.6</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Serum creatinine (mg/dL)</td><td char="." align="char">1.1</td><td char="." align="char">0.6</td><td char="." align="char">0.5</td><td char="." align="char">0.9</td><td char="." align="char">3.5</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Creatinine clearance: CLcr (mL/min)</td><td char="." align="char">71.9</td><td char="." align="char">41.1</td><td char="." align="char">8.4</td><td char="." align="char">67.2</td><td char="." align="char">269.9</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="11">(b) Sampling times and numbers of points for PPK analysis</th></tr><tr><th align="left">Time (h)</th><th align="left">0</th><th align="left">1</th><th align="left">2</th><th align="left">3</th><th align="left">4</th><th align="left">6</th><th align="left">8</th><th align="left">12</th><th align="left">24</th><th align="left">Total</th></tr></thead><tbody><tr><td align="left">Points</td><td char="." align="char">56</td><td char="." align="char">39</td><td char="." align="char">59</td><td char="." align="char">46</td><td char="." align="char">55</td><td char="." align="char">25</td><td char="." align="char">3</td><td char="." align="char">13</td><td char="." align="char">8</td><td char="." align="char">304</td></tr></tbody></table><table-wrap-foot><p>Disease (cases): membranous nephropathy (26), focal segmental glomerulosclerosis (5), IgA nephropathy (7), minimal change nephrotic syndrome (2), Henoch&#x02013;Schoenlein purpura nephritis (1), kidney transplantation (7), SLE (12), dermatomyositis (2), rheumatoid arthritis (2)</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Comparison of PPK parameters of mizoribine estimated with NONMEM analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Adult patients with kidney disease</th><th align="left">Renal transplant recipients<sup>a</sup>
</th><th align="left">Healthy male volunteers<sup>b</sup>
</th></tr></thead><tbody><tr><td align="left">No. of subjects</td><td align="left">64</td><td align="left">114</td><td align="left">36</td></tr><tr><td align="left">Samples</td><td align="left">315</td><td align="left">449</td><td align="left">446</td></tr><tr><td align="left">ALAG (h)</td><td align="left">0.675</td><td align="left">0.581</td><td align="left">0.349</td></tr><tr><td align="left">KA (h<sup>&#x02212;1</sup>)</td><td align="left">0.723</td><td align="left">0.983</td><td align="left">0.838</td></tr><tr><td align="left">V/F (L)</td><td align="left">0.744&#x000a0;&#x000d7;&#x000a0;WT</td><td align="left">0.558&#x000a0;&#x000d7;&#x000a0;WT</td><td align="left">0.834&#x000a0;&#x000d7;&#x000a0;WT</td></tr><tr><td align="left">CL/F (mL/min)</td><td align="left">2.10&#x000a0;&#x000d7;&#x000a0;CLcr</td><td align="left">1.80&#x000a0;&#x000d7;&#x000a0;CLcr</td><td align="left">1.93&#x000a0;&#x000d7;&#x000a0;CLcr</td></tr></tbody></table><table-wrap-foot><p>
<italic>ALAG</italic> absorption lag time, <italic>KA</italic> absorption rate constant, <italic>V/F</italic> apparent volume of distribution, <italic>CL/F</italic> oral clearance, <italic>WT</italic> body weight, <italic>CLcr</italic> creatinine clearance</p><p>The parameters in adult patients with kidney disease are compared with those in adult transplantation recipients<sup>a</sup> and healthy male volunteers<sup>b</sup> reported previously</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec15"><title>Estimated serum MZR concentration curves in IMN patients</title><p id="Par27">Serum MZR concentration curves and <italic>C</italic>
<sub>max</sub> of 12 patients (8 with CR and 4 with non-CR) given MZR once a day and 10 patients (6 with CR and 4 with non-CR) given MZR 3-times-a-day were estimated simultaneously by Bayesian inference based on the PPK parameters described in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). The values of assayed <italic>C</italic>
<sub>0&#x02013;4</sub> and estimated <italic>C</italic>
<sub>max</sub> in 22 patients are summarized in Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>. <italic>C</italic>
<sub>2&#x02013;4</sub> were significantly correlated with <italic>C</italic>
<sub>max</sub>, and <italic>C</italic>
<sub>3</sub> in particular showed an approximate value of <italic>C</italic>
<sub>max</sub>. There was significant difference in <italic>C</italic>
<sub>max</sub> between the two administration protocols (mean&#x000a0;&#x000b1;&#x000a0;SD 1.20&#x000a0;&#x000b1;&#x000a0;0.52 vs. 0.76&#x000a0;&#x000b1;&#x000a0;0.39&#x000a0;&#x003bc;g/mL, <italic>p</italic>&#x000a0;=&#x000a0;0.04). All patients with a <italic>C</italic>
<sub>max</sub> of &#x0003e;1.1&#x000a0;&#x003bc;g/mL, most of whom received the once-a-day regimen, achieved CR, although some with a lower concentration also achieved CR in both groups, and there was no significant difference between CR and non-CR cases (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Serum MZR concentration by Bayesian inference based on the PPK parameters following <bold>a</bold> once-a-day and <bold>b</bold> 3-times-a-day administrations. <italic>Solid and dashed curves</italic> are those of CR cases and the others, respectively</p></caption><graphic xlink:href="10157_2016_1340_Fig4_HTML" id="MO6"/></fig>
<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>The relations between assayed <italic>C</italic>
<sub>0&#x02013;4</sub> and estimated <italic>C</italic>
<sub>max</sub> for 22 patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Mean&#x000a0;&#x000b1;&#x000a0;SD (&#x003bc;g/mL)</th><th align="left">Pearson&#x02019;s correlation coefficient*</th><th align="left">
<italic>p</italic>*</th></tr></thead><tbody><tr><td align="left">
<italic>C</italic>
<sub>0</sub>
</td><td char="&#x000b1;" align="char">0.045&#x000a0;&#x000b1;&#x000a0;0.076</td><td align="left">&#x02212;0.319</td><td align="left">ns</td></tr><tr><td align="left">
<italic>C</italic>
<sub>1</sub>
</td><td char="&#x000b1;" align="char">0.225&#x000a0;&#x000b1;&#x000a0;0.202</td><td align="left">&#x02212;0.009</td><td align="left">ns</td></tr><tr><td align="left">
<italic>C</italic>
<sub>2</sub>
</td><td char="&#x000b1;" align="char">0.678&#x000a0;&#x000b1;&#x000a0;0.414</td><td align="left">0.857</td><td align="left">&#x0003c;0.01</td></tr><tr><td align="left">
<italic>C</italic>
<sub>3</sub>
</td><td char="&#x000b1;" align="char">0.991&#x000a0;&#x000b1;&#x000a0;0.556</td><td align="left">0.984</td><td align="left">&#x0003c;0.01</td></tr><tr><td align="left">
<italic>C</italic>
<sub>4</sub>
</td><td char="&#x000b1;" align="char">1.057&#x000a0;&#x000b1;&#x000a0;0.609</td><td align="left">0.962</td><td align="left">&#x0003c;0.01</td></tr><tr><td align="left">
<italic>C</italic>
<sub>max</sub>
</td><td char="&#x000b1;" align="char">0.998&#x000a0;&#x000b1;&#x000a0;0.506</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr></tbody></table><table-wrap-foot><p>
<italic>ns</italic> not significance</p><p>*&#x000a0;Between each assayed serum concentration and estimated <italic>C</italic>
<sub>max</sub>
</p></table-wrap-foot></table-wrap>
</p><p id="Par28">ROC curves were drawn to detect the optimum cutoff level of <italic>C</italic>
<sub>max</sub> for CR in once-a-day and 3-times-a-day administrations, respectively (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). The area under ROC curves were 0.813&#x000a0;&#x000b1;&#x000a0;0.126 (95&#x000a0;% CI 0.565&#x02013;1.000) in once-a-day administration and 0.524&#x000a0;&#x000b1;&#x000a0;0.184 (95&#x000a0;% CI 0.163&#x02013;0.885) in 3-times-a-day administration. From these results, the optimum cutoff point for <italic>C</italic>
<sub>max</sub> was determined to be 1.1&#x000a0;&#x003bc;g/mL (sensitivity 0.625, specificity 1.000) in once-a-day administration but not in 3-times-a-day administration.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Receiver operator characteristic (ROC) curves for serum MZR concentration in once-a-day and 3-times-a-day administrations. The optimal cutoff level of <italic>C</italic>
<sub>max</sub> for CR was determined to be 1.1&#x000a0;&#x003bc;g/mL (sensitivity 0.625, specificity 1.000) in once-a-day administration (<italic>arrow</italic>)</p></caption><graphic xlink:href="10157_2016_1340_Fig5_HTML" id="MO7"/></fig>
</p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par30">Combined administration of immunosuppressants with steroids has been reported to be useful for the treatment of IMN with associated SRNS. In the KDIGO (Kidney Disease: Improving Global Outcomes) Clinical and Practice Guideline published in 2012 [<xref ref-type="bibr" rid="CR2">2</xref>], the initial use of cyclophosphamide (CPA), an alkylating agent, with steroids was recommended on the basis of existing evidence accumulated from many randomized controlled trials conducted over the last few decades. However, a cohort study of 1000 cases conducted in Japan did not demonstrate any superiority of combined therapy with steroids and CPA over steroid monotherapy [<xref ref-type="bibr" rid="CR1">1</xref>]. Moreover, the use of CPA has been associated with adverse events such as neoplasia, agranulocytosis and viral hepatitis, which can sometimes be fatal. On the other hand, cyclosporine (CyA), a calcineurin inhibitor, has been used as an effective agent for IMN with SRNS [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>] and its combination with steroids is recommended in some guidelines for SRNS therapy [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. However, CyA also has serious adverse effects such as nephrotoxicity and hypertension, and is not suitable for long-term therapy. From this viewpoint, MZR is known not to have serious adverse events and to be beneficial when administered over a long period [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par31">MZR is an imidazole nucleotide that inhibits purine synthesis and T and B lymphocyte proliferations [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. These actions are very similar to those of MMF, but less myelosuppressive and less hepatotoxic [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. In the present trial, two patients had to be withdrawn due to brain tumor and thyroid tumor, respectively, but these were accidental events and any serious adverse effects induced by MZR were not found. Although it was assumed that hyperuricemia would occur, in view of the inhibitory effect of MZR on purine synthesis, no severe hyperlipidemia or gout was recognized. Moreover, no marked liver dysfunction was recorded. Thus, in agreement with other studies [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>], our results indicate that MZR is a safe immunosuppressant for long-term use.</p><p id="Par32">MZR has been approved for administration at 50&#x000a0;mg 3-times-a-day with steroids for treatment of nephrotic syndrome by health insurance system in Japan. On the other hand, it has been suggested that once-a-day administration can achieve a higher serum MZR concentration and be more beneficial for intensive immunosuppression in patients with systemic lupus erythematosus [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>] or renal transplantation [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Therefore, in the present study, we compared the once-a-day and 3-times-a-day administration protocols. We found that the cumulative CR ratio in the once-a-day group was increased during 2&#x000a0;years of treatment, although Kaplan&#x02013;Meier analysis indicated no significant difference between the two administration protocols (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). In addition, the remission (CR&#x000a0;+&#x000a0;ICR) rates of &#x0003e;50&#x000a0;% in both groups were equal to that in a PSL and MZR-treated group (55&#x000a0;%) and much better than that in a PSL-alone group (17&#x000a0;%) in a previous postmarketing randomized controlled trial [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par33">To clarify the relationship between MZR dose regimens and response, we estimated the serum MZR concentration curve and <italic>C</italic>
<sub>max</sub> based on PPK analysis and verified that the levels of these parameters were related to the MZR dosage schedule and reflected remission of NS. MZR is absorbed from the gastrointestinal tract after oral administration, and the unchanged drug is excreted predominantly into the urine. The PPK of MZR is well described by a simple one-compartment model with first-order absorption. Accordingly, the MZR concentration curve and C<sub>max</sub> were previously estimated based on PPK analysis in healthy subjects [<xref ref-type="bibr" rid="CR16">16</xref>], renal transplant recipients [<xref ref-type="bibr" rid="CR17">17</xref>] and pediatric patients with kidney disease [<xref ref-type="bibr" rid="CR27">27</xref>]. However, this is the first time that the MZR concentration curve and <italic>C</italic>
<sub>max</sub> based on PPK analysis in adult patients with kidney disease were applied for the therapeutic response in NS. Once-a-day administration of MZR induced significantly higher <italic>C</italic>
<sub>max</sub> levels than 3-times-a-day administration, although individual <italic>C</italic>
<sub>max</sub> levels were widely distributed (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Actually, several studies suggest that the bioavailability of MZR in each patient is influenced by the intestinal absorption based on polymorphism of concentrative nucleoside transporter 1 gene [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>] and salt intake [<xref ref-type="bibr" rid="CR30">30</xref>]. Therefore, the wide distribution of <italic>C</italic>
<sub>max</sub> was already reported in transplanted recipients [<xref ref-type="bibr" rid="CR17">17</xref>] and pediatric patients [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par34">Meanwhile, all patients with a <italic>C</italic>
<sub>max</sub> of &#x0003e;1.1&#x000a0;&#x003bc;g/mL achieved CR as well as some with lower <italic>C</italic>
<sub>max</sub> values in both administration groups. In addition, ROC analysis showed that the optimum <italic>C</italic>
<sub>max</sub> cutoff point for CR was determined to be 1.1&#x000a0;&#x003bc;g/mL in once-a-day administration alone, and suggested the favorable therapeutic effect of once-a-day administration.</p><p id="Par35">Since our previous cohort study of 1000 cases in Japan [<xref ref-type="bibr" rid="CR1">1</xref>] found that IMN with NS was frequently responsive to steroid monotherapy, it is possible that CR would be achieved even in patients with a low <italic>C</italic>
<sub>max</sub> of MZR if steroids are given. On the other hand, several recent studies have shown that MZR enhances steroid receptor activity via 14-3-3 proteins corresponding to a blood MZR level [<xref ref-type="bibr" rid="CR31">31</xref>] and that the clinical efficacy of MZR may be dependent on <italic>C</italic>
<sub>max</sub> [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Therefore, a high <italic>C</italic>
<sub>max</sub> level may be necessary to achieve remission in nephrotic syndrome. From this viewpoint, once-a-day administration and increase of MZR dose to reach the cutoff level while monitoring <italic>C</italic>
<sub>max</sub> may be favorable if any side effects are not recognized. When it is difficult to estimate <italic>C</italic>
<sub>max</sub> practically, <italic>C</italic>
<sub>3</sub> can be used in place of <italic>C</italic>
<sub>max</sub> because <italic>C</italic>
<sub>3</sub> is an approximate value of <italic>C</italic>
<sub>max</sub> (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). However, our trial was an open multicenter postmarketing study in which the dose of MZR was limited to within 150&#x000a0;mg/day, i.e., the dosage approved by the health insurance system in Japan. Accordingly, to obtain more precise data on the inter-relationship of administration dose with the serum concentration and effectiveness of MZR, further studies with a larger cohort showing a higher dose will be needed.</p><p id="Par36">In conclusion, MZR is a safe and effective immunosuppressive agent. The combination of PSL and MZR will be useful for treatment of IMN with SRNS if once-day-administration of MZR can achieve more than 1.1&#x000a0;&#x000b5;g/mL of <italic>C</italic>
<sub>max</sub>. To predict the response of MZR, it is important to assay its serum concentration and to estimate <italic>C</italic>
<sub>max</sub> based on the PPK parameters of MZR.</p></sec></body><back><app-group><app id="App1"><sec id="Sec17"><title>Appendix: The following members organized the trial</title><p id="Par40">
<bold>Organizer</bold> Takao Saito.</p><p id="Par41">
<bold>Protocol committee</bold> Hiroshi Sato, Shinichi Nishi, Tetsuya Mitarai, Koichi Matsumoto, Ashio Yoshimura, Hitoshi Yokoyama, Masayuki Iwano, Noriaki Yorioka, and Takao Saito.</p><p id="Par42">
<bold>Assessment committee</bold> Yasuhiko Tomino, Akio Koyama, and Shiro Ueda.</p><p id="Par43">
<bold>Statistics committee</bold> Yasufumi Kataoka, Satoru Ogahara, and Yoshie Sasatomi</p><p id="Par44">
<bold>Advisory committee</bold> Seiichi Matsuo, Enyu Imai, Masaomi Nangaku, and Shoichi Maruyama</p><p id="Par45">
<italic>The following investigators participated in the trial</italic>
</p><p id="Par46">Saitama Medical University: Tetsuya Mitarai, Hajime Hasegawa and Koichi Togasawa; Nihon University: Koichi Matsumoto and Takayuki Fujita; Showa University Fujigaoka Hospital: Ashio Yoshimura, Yoshikuni Nagayama and Takahiro Nakayama; The Jikei University: Tetsuya Kawamura and Hideo Okonogi; Tokyo Women&#x02019;s Medical University: Wako Yumura, Minako Koike, and Masayo Naito; St. Marianna University School of Medicine: Kenjiro Kimura and Yasuda Takashi; Dokkyo Medical University: Toshihiko Ishimitsu and Hidehiko Ono; Toho University: Sonoo Mizuiri; Tokyo Medical University Hachioji Medical Center: Masaharu Yoshida and Masakazu Akashi; Fujita Health University: Satoshi Sugiyama; Nara Medical University: Masayuki Iwano; Kitano Hospital: Eri Muso; Kanazawa University: Hitoshi Yokoyama; Okayama University: Hirofumi Makino and Yohei Maeshima; Hiroshima University: Noriaki Yorioka and Takao Masaki; Shimane University: Takafumi Ito; Fukuoka University: Takao Saito, Satoru Ogahara and Yoshie Sasatomi; Kurume University: Keisuke Kono.</p></sec></app></app-group><fn-group><fn><p>The other authors &#x0201c;on behalf of the Refractory Nephrotic Syndrome Study Group&#x0201d; are listed in the Appendix.</p></fn></fn-group><ack><p>This study was supported by a grant for Progressive Renal Disease Research Projects from the Ministry of Health, Labor and Welfare, Japan, and by a grant from the Japan Kidney Foundation. The authors greatly acknowledge the help and assistance of many colleagues in the centers and affiliated hospitals participating in this trial. We thank Dr. M. Watanabe for supporting the data arrangement. We also appreciate Asahi-Kasei Pharma, Tokyo, and Toyo Kensa Center, Shizuoka, for measurement of the serum MZR concentration and conducting PPK analysis. Although these measurement and analysis were performed by the special techniques of these institutions, the content and drafting of this paper were not influenced by them.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflict of interest</title><p id="Par37">T Saito and N&#x000a0;Yorioka have received research funds from Asahi Kasei Pharma. T Mitarai has received lecturer&#x02019;s fee from Asahi Kasei Pharma. Other authors have declared that no conflicts of interest exist.</p></sec><sec id="FPar2"><title>Ethical approval</title><p id="Par38">This study was approved by the Clinical Study Review Board at Fukuoka University Hospital (Approval No. 03-128). The institutional review boards at the collaborating institutions also approved the protocol when requested. All procedures were performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments, or comparable ethical standards.</p></sec><sec id="FPar3"><title>Informed consent</title><p id="Par39">Written informed consent was obtained before patient enrollment and after a thorough explanation of the trial&#x02019;s objectives, duration, and structure. The availability of alternative drugs, the possibility of adverse reactions, privacy measures, and the voluntary nature of the trial, including the right to withdraw without repercussions, were all carefully explained.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiiki</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Nishitani</surname><given-names>Y</given-names></name><name><surname>Mitarai</surname><given-names>T</given-names></name><name><surname>Yorioka</surname><given-names>N</given-names></name><name><surname>Yoshimura</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan</article-title><source>Kidney Int</source><year>2004</year><volume>65</volume><fpage>1400</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00518.x</pub-id><pub-id pub-id-type="pmid">15086481</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cattran</surname><given-names>DC</given-names></name><name><surname>Feehally</surname><given-names>J</given-names></name><name><surname>Cook</surname><given-names>HT</given-names></name><etal/></person-group><article-title>KDIGO clinical practice guideline for glomerulonephritis</article-title><source>Kidney Int Suppl</source><year>2012</year><volume>2</volume><fpage>S139</fpage><lpage>S274</lpage><pub-id pub-id-type="doi">10.1038/kisup.2012.9</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cattran</surname><given-names>DC</given-names></name><name><surname>Alexopoulos</surname><given-names>E</given-names></name><name><surname>Heering</surname><given-names>P</given-names></name><name><surname>Hoyer</surname><given-names>PF</given-names></name><name><surname>Johnston</surname><given-names>A</given-names></name><name><surname>Meyrier</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations</article-title><source>Kidney Int</source><year>2007</year><volume>72</volume><fpage>1429</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5002553</pub-id><pub-id pub-id-type="pmid">17898700</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Yoshikawa</surname><given-names>N</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><etal/></person-group><article-title>A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome</article-title><source>Kidney Int</source><year>2000</year><volume>58</volume><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2000.00168.x</pub-id><pub-id pub-id-type="pmid">10886577</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibasaki</surname><given-names>T</given-names></name><name><surname>Koyama</surname><given-names>A</given-names></name><name><surname>Hishida</surname><given-names>A</given-names></name><name><surname>Muso</surname><given-names>E</given-names></name><name><surname>Osawa</surname><given-names>G</given-names></name><name><surname>Yamabe</surname><given-names>H</given-names></name><etal/></person-group><article-title>A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey)</article-title><source>Clin Exp Nephrol.</source><year>2004</year><volume>8</volume><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1007/s10157-004-0276-0</pub-id><pub-id pub-id-type="pmid">15235928</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Nojima</surname><given-names>Y</given-names></name><name><surname>Moriki</surname><given-names>T</given-names></name></person-group><article-title>Efficacy of mizoribine followed by low-dose prednisone in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria</article-title><source>Ren Fail</source><year>2013</year><volume>35</volume><fpage>936</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.3109/0886022X.2013.808133</pub-id><pub-id pub-id-type="pmid">23815417</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Mochizuki</surname><given-names>K</given-names></name><name><surname>Oka</surname><given-names>T</given-names></name><name><surname>Hanada</surname><given-names>K</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name></person-group><article-title>Study of mizoribine therapy in elderly patients with membranous nephropathy: comparison with patients not receiving mizoribine</article-title><source>Int Urol Nephrol</source><year>2015</year><volume>47</volume><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1007/s11255-014-0850-7</pub-id><pub-id pub-id-type="pmid">25298141</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonda</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name><name><surname>Funchinoue</surname><given-names>S</given-names></name><name><surname>Hayasaka</surname><given-names>Y</given-names></name><name><surname>Kawaguchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clinical pharmacokinetic study of mizoribine in renal transplantation patients</article-title><source>Transplant Proc.</source><year>1996</year><volume>28</volume><fpage>3643</fpage><lpage>3648</lpage><pub-id pub-id-type="pmid">8962403</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>H</given-names></name><name><surname>Tsuji</surname><given-names>M</given-names></name></person-group><article-title>Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells</article-title><source>Biochem Pharmacol</source><year>1983</year><volume>32</volume><fpage>3547</fpage><lpage>3553</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(83)90301-5</pub-id><pub-id pub-id-type="pmid">6140013</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusumi</surname><given-names>T</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name><name><surname>Katsunuma</surname><given-names>T</given-names></name><name><surname>Yamamura</surname><given-names>M</given-names></name></person-group><article-title>Dual inhibitory effect of bredinin</article-title><source>Cell Biochem Funct</source><year>1989</year><volume>7</volume><fpage>201</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1002/cbf.290070308</pub-id><pub-id pub-id-type="pmid">2791214</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajo</surname><given-names>A</given-names></name><name><surname>Khoshnoodi</surname><given-names>J</given-names></name><name><surname>Takenaka</surname><given-names>H</given-names></name><name><surname>Hagiwara</surname><given-names>E</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Kawakami</surname><given-names>H</given-names></name><etal/></person-group><article-title>Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance</article-title><source>J Am Soc Nephrol</source><year>2007</year><volume>18</volume><fpage>2554</fpage><lpage>2564</lpage><pub-id pub-id-type="doi">10.1681/ASN.2006070732</pub-id><pub-id pub-id-type="pmid">17687078</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishioka</surname><given-names>Y</given-names></name><name><surname>Horita</surname><given-names>Y</given-names></name><name><surname>Tadokoro</surname><given-names>M</given-names></name><name><surname>Taura</surname><given-names>K</given-names></name><name><surname>Suyama</surname><given-names>N</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Changing mizoribine administration from three divided doses to one single dose induced remission of relapsed membranous nephropathy</article-title><source>Nephrol Dial Transplant</source><year>2006</year><volume>21</volume><fpage>2337</fpage><lpage>2338</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfl108</pub-id><pub-id pub-id-type="pmid">16547120</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Ichinose K1, Origuchi T, Kawashiri SY, Iwamoto N, Fujikawa K, Aramaki T, et al. Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis. Intern Med. 2010;49:2211&#x02013;8.</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Ehrenreich T, Churg J. Pathology of membranous nephropathy. In: Sommers SC, editor. The Pathology Annual no. 3. New York: Appleton-Century-Crofts; 1968;145&#x02013;186.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosotsubo</surname><given-names>H</given-names></name><name><surname>Takahara</surname><given-names>S</given-names></name><name><surname>Taenaka</surname><given-names>N</given-names></name></person-group><article-title>Simplified high-performance liquid chromatographic method for determination of mizoribine in human serum</article-title><source>J Chromatogr</source><year>1988</year><volume>432</volume><fpage>340</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1016/S0378-4347(00)80663-5</pub-id><pub-id pub-id-type="pmid">3065347</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name></person-group><article-title>Population pharmacokinetics of higher-dose mizoribine in healthy male volunteers</article-title><source>Biol Pharm Bull</source><year>2006</year><volume>29</volume><fpage>2460</fpage><lpage>2464</lpage><pub-id pub-id-type="doi">10.1248/bpb.29.2460</pub-id><pub-id pub-id-type="pmid">17142982</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>K</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Ishibashi</surname><given-names>M</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name></person-group><article-title>Population pharmacokinetics of mizoribine in adult recipients of renal transplantation</article-title><source>Clin Exp Nephrol</source><year>2011</year><volume>15</volume><fpage>900</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1007/s10157-011-0487-0</pub-id><pub-id pub-id-type="pmid">21751083</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cattran</surname><given-names>DC</given-names></name><name><surname>Appel</surname><given-names>GB</given-names></name><name><surname>Hebert</surname><given-names>LA</given-names></name><name><surname>Hunsicker</surname><given-names>LG</given-names></name><name><surname>Pohl</surname><given-names>MA</given-names></name><name><surname>Hoy</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial</article-title><source>Kidney Int</source><year>2001</year><volume>59</volume><fpage>1484</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2001.0590041484.x</pub-id><pub-id pub-id-type="pmid">11260412</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexopoulos</surname><given-names>E</given-names></name><name><surname>Papagianni</surname><given-names>A</given-names></name><name><surname>Tsamelashvili</surname><given-names>M</given-names></name><name><surname>Leontsini</surname><given-names>M</given-names></name><name><surname>Memmos</surname><given-names>D</given-names></name></person-group><article-title>Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome</article-title><source>Nephrol Dial Transplant</source><year>2006</year><volume>21</volume><fpage>3127</fpage><lpage>3132</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfl360</pub-id><pub-id pub-id-type="pmid">16968719</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Iwano</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Mitarai</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Yorioka</surname><given-names>N</given-names></name><etal/></person-group><article-title>Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial</article-title><source>Clin Exp Nephrol</source><year>2014</year><volume>18</volume><fpage>784</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1007/s10157-013-0925-2</pub-id><pub-id pub-id-type="pmid">24363128</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahara</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Akiyama</surname><given-names>T</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name><name><surname>Amada</surname><given-names>N</given-names></name><etal/></person-group><article-title>Randomized comparative trial of mizoribine versus mycophenolate mofetil in combination with tacrolimus for living donor renal transplantation</article-title><source>Clin Exp Nephrol</source><year>2013</year><volume>17</volume><fpage>899</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1007/s10157-013-0780-1</pub-id><pub-id pub-id-type="pmid">23430390</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name></person-group><article-title>Comparative efficacy and safety of mizoribine with mycophenolate mofetil for Asian renal transplantation&#x02013;a meta-analysis</article-title><source>Clin Biochem</source><year>2014</year><volume>7</volume><fpage>663</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2014.01.014</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Tsugawa</surname><given-names>K</given-names></name><name><surname>Nakahata</surname><given-names>T</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>E</given-names></name></person-group><article-title>Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis</article-title><source>Clin Nephrol</source><year>2005</year><volume>63</volume><fpage>417</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.5414/CNP63417</pub-id><pub-id pub-id-type="pmid">15960142</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Nozu K, Iijima K, Kamioka I, Fujita T, Yoshiya K, Tanaka R. et al. High-dose mizoribine treatment for adolescents with systemic lupus erythematosus. Pediatr Int. 2006;48:152&#x02013;7.</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Yoshikawa</surname><given-names>N</given-names></name><name><surname>Hattori</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><name><surname>Ando</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial</article-title><source>Pediatr Nephrol</source><year>2010</year><volume>25</volume><fpage>877</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1007/s00467-009-1341-4</pub-id><pub-id pub-id-type="pmid">19902267</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Mikami</surname><given-names>H</given-names></name><name><surname>Matsuoka</surname><given-names>H</given-names></name><name><surname>Irie</surname><given-names>S</given-names></name><name><surname>Abe</surname><given-names>Y</given-names></name><name><surname>Sasatomi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Experiences of high-dose mizoribine as antimetabolite immunosuppressants for kidney transplantation</article-title><source>Transplant Proc.</source><year>2012</year><volume>44</volume><fpage>150</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2011.11.020</pub-id><pub-id pub-id-type="pmid">22310602</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneda</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Ohta</surname><given-names>K</given-names></name><name><surname>Ushijima</surname><given-names>K</given-names></name><name><surname>Gotoh</surname><given-names>Y</given-names></name><name><surname>Satomura</surname><given-names>K</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of mizoribine in pediatric patients with kidney disease</article-title><source>Clin Exp Nephrol</source><year>2015</year><volume>20</volume><fpage>757</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1007/s10157-015-1209-9</pub-id><pub-id pub-id-type="pmid">26649561</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naito</surname><given-names>T</given-names></name><name><surname>Tokashiki</surname><given-names>S</given-names></name><name><surname>Mino</surname><given-names>Y</given-names></name><name><surname>Otsuka</surname><given-names>A</given-names></name><name><surname>Ozono</surname><given-names>S</given-names></name><name><surname>Kagawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2010</year><volume>106</volume><fpage>310</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">19912163</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukao</surname><given-names>M</given-names></name><name><surname>Ishida</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Taguchi</surname><given-names>M</given-names></name><name><surname>Matsukura</surname><given-names>H</given-names></name><name><surname>Miyawaki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males</article-title><source>Drug Metab Pharmacokinet</source><year>2011</year><volume>26</volume><fpage>538</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.2133/dmpk.DMPK-11-NT-040</pub-id><pub-id pub-id-type="pmid">21727755</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>K</given-names></name><name><surname>Fukao</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Taguchi</surname><given-names>M</given-names></name><name><surname>Miyawaki</surname><given-names>T</given-names></name><name><surname>Matsukura</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effect of salt intake on bioavailability of mizoribine in healthy Japanese males</article-title><source>Drug Metab Pharmacokinet</source><year>2013</year><volume>28</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.2133/dmpk.DMPK-12-NT-043</pub-id><pub-id pub-id-type="pmid">22813716</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Wakui</surname><given-names>H</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Zilliacus</surname><given-names>J</given-names></name><name><surname>Itoh</surname><given-names>H</given-names></name></person-group><article-title>Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein</article-title><source>Biochem Biophys Res Commun.</source><year>2000</year><volume>274</volume><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.3104</pub-id><pub-id pub-id-type="pmid">10903900</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Tsugawa</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Nakahata</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>E</given-names></name></person-group><article-title>Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis</article-title><source>Pediatr Nephrol</source><year>2006</year><volume>21</volume><fpage>962</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1007/s00467-006-0120-8</pub-id><pub-id pub-id-type="pmid">16773408</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Oki</surname><given-names>E</given-names></name><name><surname>Tsuruga</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Matsukura</surname><given-names>H</given-names></name><name><surname>Matsunaga</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the Tohoku Pediatric Study Group</article-title><source>Nephron Clin Pract</source><year>2008</year><volume>110</volume><fpage>c73</fpage><lpage>c79</lpage><pub-id pub-id-type="doi">10.1159/000151721</pub-id><pub-id pub-id-type="pmid">18758186</pub-id></element-citation></ref></ref-list></back></article>